Grace Therapeutics, Inc.
GRCENasdaqCIK 1444192HealthcareFiscal year ends Mar 31
Latest reported revenue, Q4 FY2022$100.0mRevenue, Q4 FY2022, three months to 2022-03-31$100.0m. XBRL concept
us-gaap:Revenues. 10-K filed 2023-06-23, accession 0000950170-23-029498. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Mar 31, 2022, from the 10-K filed Jun 23, 2023.Latest quarter: Q1 FY2027
Three months to Jun 30, 2026, against the same quarter a year earlier.
- Revenuenot reported (Revenue not reported)No year-earlier figure to compare
- Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
- Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
- Net marginnot reported (Revenue not reported)No year-earlier figure to compare
- Diluted EPS−$0.91Diluted EPS, Q1 FY2027, three months to 2026-06-30−$0.91 per share. XBRL concept
us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001140361-26-032632.Report this figure−333.3% on a year earlier - Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare
Last eight quarters
Full statements| Line item | Unit | Q2 FY20252024-09-30 | Q3 FY20252024-12-31 | Q4 FY20252025-03-31 | Q1 FY20262025-06-30 | Q2 FY20262025-09-30 | Q3 FY20262025-12-31 | Q4 FY20262026-03-31 | Q1 FY20272026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $ | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | (0.30)Diluted EPS, Q2 FY2025, three months to 2024-09-30−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001140361-25-041804.Report this figure | (0.36)Diluted EPS, Q3 FY2025, three months to 2024-12-31−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-12, accession 0001140361-26-004924.Report this figure | not reported (Diluted EPS not reported) | (0.21)Diluted EPS, Q1 FY2026, three months to 2025-06-30−$0.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001140361-26-032632.Report this figure | (0.06)Diluted EPS, Q2 FY2026, three months to 2025-09-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001140361-25-041804.Report this figure | (0.14)Diluted EPS, Q3 FY2026, three months to 2025-12-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-12, accession 0001140361-26-004924.Report this figure | not reported (Diluted EPS not reported) | (0.91)Diluted EPS, Q1 FY2027, three months to 2026-06-30−$0.91 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001140361-26-032632.Report this figure | |
| Free cash flow | $ | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20222022-03-31 | FY20232023-03-31 | FY20242024-03-31 | FY20252025-03-31 | FY20262026-03-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $m | 100Revenue, FY2022, twelve months to 2022-03-31$100.0m. XBRL concept us-gaap:Revenues. 10-K filed 2023-06-23, accession 0000950170-23-029498.Report this figure | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | (15.6%)Operating margin, FY2022, twelve months to 2022-03-31. operating income / revenueOperating income: −$15.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-06-23, accession 0000950170-23-029498.Revenue: $100.0m. XBRL concept us-gaap:Revenues. 10-K filed 2023-06-23, accession 0000950170-23-029498.Report this figure | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Net margin | % | (9.8%)Net margin, FY2022, twelve months to 2022-03-31. net income / revenueNet income: −$9.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-06-23, accession 0000950170-23-029498.Revenue: $100.0m. XBRL concept us-gaap:Revenues. 10-K filed 2023-06-23, accession 0000950170-23-029498.Report this figure | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | (0.27)Diluted EPS, FY2022, twelve months to 2022-03-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-06-23, accession 0000950170-23-029498.Report this figure | (5.71)Diluted EPS, FY2023, twelve months to 2023-03-31−$5.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-06-21, accession 0000950170-24-075875.Report this figure | (1.35)Diluted EPS, FY2024, twelve months to 2024-03-31−$1.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-06-23, accession 0001140361-25-023259.Report this figure | (0.79)Diluted EPS, FY2025, twelve months to 2025-03-31−$0.79 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-06-18, accession 0001140361-26-025662.Report this figure | (0.47)Diluted EPS, FY2026, twelve months to 2026-03-31−$0.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-06-18, accession 0001140361-26-025662.Report this figure | |
| Free cash flow | $m | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
| Date | Insider | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-10-26 | Opaleye Management Inc.10% owner | Purchase | 66,411 | $1.7679 | $117.4k | Form 4 |
| 2026-10-22 | Opaleye Management Inc.10% owner | Purchase | 21,390 | $1.9258 | $41.2k | Form 4 |
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| Cerity Partners LLC | 2026-06-30 | $1.9m | 849,055 | Unchanged | |
| Eversept Partners, LP | 2026-06-30 | $1.8m | 772,900 | Added+16,300 | |
| BANK OF AMERICA CORP /DE/ | 2026-06-30 | $1.1m | 494,698 | Reduced−25 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2026-06-30 | $934.6k | 411,714 | Added+10,058 | |
| CITADEL ADVISORS LLC | 2026-06-30 | $793.9k | 349,740 | Added+250,998 | |
| Maven Securities LTD | 2026-06-30 | $454.0k | 200,000 | New+200,000 | |
| Birchview Capital, LP | 2026-06-30 | $272.4k | 120,000 | Added+70,000 | |
| CANTOR FITZGERALD, L. P. | 2026-06-30 | $227.0k | 100,000 | New+100,000 | |
| CANTOR FITZGERALD, L. P. | 2026-06-30 | $227.0k | 100,000 | New+100,000 | |
| TWO SIGMA INVESTMENTS, LP | 2026-06-30 | $219.9k | 96,890 | New+96,890 |
Recent filings
All 589 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-1816:06 ET | 8-K | 5.07 Shareholder vote results | 0001140361-26-037114 |
| 2026-08-1308:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-032644 |
| 2026-08-1307:30 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001140361-26-032632 |
| 2026-08-0616:06 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-031671 |
| 2026-07-2816:29 ET | DEF 14A | Proxy statementPeriod 2026-09-17 | 0001140361-26-029889 |
| 2026-07-2807:16 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-029837 |
| 2026-06-1808:15 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-025669 |
| 2026-06-1808:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-025667 |
| 2026-06-1807:31 ET | 10-K | Annual reportPeriod 2026-03-31 | 0001140361-26-025662 |
| 2026-06-0516:09 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001140361-26-024269 |
Latest annual report
Form 10-K for the fiscal year ended Mar 31, 2026Filed Jun 18, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1444192
- Tickers
- GRCE
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Mar 31
- Incorporated in
- DE
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Former names
- Acasti Pharma Inc. (to 2024-10-25)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 18:07 ET. Listed shows no prices and gives no investment advice.